This trial will test how safe and effective GEN1042 is in treating patients with metastatic or locally advanced solid tumors.
8 Primary · 19 Secondary · Reporting Duration: From the start of study treatment until death due to any cause, assessed up to 36 months after the last subject's first treatment in the trial.
Experimental Treatment
647 Total Participants · 12 Treatment Groups
Primary Treatment: GEN1042 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: